-
GPR68–ATF4 Signaling in GBM Ferroptosis
2026-08-27
Williams et al. identify an acid-activated GPR68–ATF4 pathway that helps glioblastoma cells survive their acidic extracellular environment. Their genetic, pharmacological, transcriptomic, and ultrastructural evidence indicates that GPR68 inhibition induces ferroptotic death across heterogeneous glioblastoma models while sparing non-malignant neural cells, providing a mechanistic framework for targeting tumor-microenvironment adaptation.
-
HCAR3 Agonist Selectivity: Cryo-EM Insights
2026-08-27
A 2025 PLOS Biology study uses cryo-EM structures and cAMP assays to explain how selective agonists recognize HCAR3 and discriminate it from HCAR2. The work identifies orthosteric-pocket geometry and specific aromatic and residue-level interactions, including those observed with Acifran, providing a framework for lipid metabolism and metabolic disorder research.
-
Caspofungin: Translational Lessons for Resistant Candida
2026-08-26
Caspofungin links fungal cell wall biology to practical translational strategy. By examining its mechanism, performance in a delayed-treatment Candida auris model, and role as a benchmark for emerging glucan-synthesis inhibitors, researchers can design more decision-relevant antifungal studies.
-
Entinostat: Separating Growth Arrest From Cell Death
2026-08-26
Entinostat (MS-275) is a selective class I HDAC inhibitor whose effects can be misread when viability and cell death are treated as equivalent. This guide combines target biology with dissertation-based assay principles to improve cancer response interpretation, including retinoblastoma and solid tumor research.
-
o-Agatoxin IVA in Cortical Excitotoxicity
2026-08-25
Lustig, Ahern, and Greenberg tested whether blocking P/Q-type voltage-gated calcium channels with ω-agatoxin IVA protects cultured cortical neurons from excitotoxic injury. The study found no reduction in LDH-defined toxicity after veratridine, ouabain, or NMDA challenges, showing that inhibition of glutamate release does not necessarily translate into neuronal protection.
-
Rotigotine Workflows for Dopaminergic Research
2026-08-25
Build more interpretable Parkinson’s disease and depression studies with Rotigotine, a dopamine D2/D3 receptor agonist that supports receptor, oxidative-stress, cellular, and behavioral readouts. This workflow emphasizes dose separation, exposure control, and locomotor-confound management so apparent antidepressant or neuroprotective effects are not mistaken for nonspecific stimulation.
-
Cyclophilin A and Cyclosporine Resistance in Mice
2026-08-24
The reference study used Ppia-deficient mice and immune cells to show that Cyclophilin A is the primary mediator of cyclosporine-mediated immunosuppression. Its genetic, cellular, and in vivo evidence connects drug resistance to reduced calcineurin inhibition and clarifies how Cyclosporin A blocks T-cell responses.
-
Milk EV Uptake in Porcine Intestinal Organoids
2026-08-24
This study establishes three porcine intestinal stem cell–based models to examine how milk-derived extracellular vesicles are internalized across intestinal regions and epithelial polarities. Its findings connect apical accessibility, extracellular vesicle uptake, and colon stemness-related responses while showing that endocytosis inhibitors suppress vesicle internalization.
-
ApexPrep DNA Plasmid Miniprep Kit for AML Research
2026-08-23
Build reliable plasmid DNA extraction for cloning, sequencing, and AML perturbation studies with one alkaline-lysis workflow for high- and low-copy vectors. The ApexPrep DNA Plasmid Miniprep Kit combines rapid membrane purification with practical checkpoints that help protect downstream digestion, transformation, sequencing, and robust-cell-line transfection.
-
NAT1–ENO1–Lactate Axis in Colorectal Cancer
2026-08-22
A 2026 MedComm study defines NAT1 as a metabolic–immune regulator that restrains ENO1 activity, lactate production, and TRAF6-dependent PD-L1 stabilization in colorectal cancer. Its integrated database, multi-omics, cellular, patient, and mouse-model evidence provides a mechanistic rationale for testing lactate-pathway perturbation alongside immune checkpoint blockade, while remaining preclinical.
-
Acifran Workflows for Lipid Signaling Research
2026-08-21
Acifran enables receptor-proximal studies of HCAR2/GPR109A and HCAR3/GPR109B signaling, linking cAMP responses to lipid metabolism phenotypes. This workflow-focused guide covers stock preparation, comparative receptor assays, structure-informed experiments, and practical troubleshooting.
-
Rapamycin in Obesity: An mTOR Assay Strategy
2026-08-20
Rapamycin (Sirolimus) can serve as a mechanistic probe for testing how mTOR signaling intersects with macrophage–adipose stem cell communication and ferroptosis. This article translates a recent obesity study into an assay strategy while defining what Rapamycin can—and cannot—prove.
-
Deferasirox Fe3+ Chelate: From Binding to Translation
2026-08-20
A mechanistic and translational framework for using Deferasirox Fe3+ chelate in iron overload treatment research, with practical guidance for beta-thalassemia, chronic anemia, assay design, and research reproducibility.
-
Dexamethasone for Inflammation Research
2026-08-19
Dexamethasone (DHAP) provides a defined glucocorticoid anti-inflammatory reference for modeling NF-κB activity, stem cell differentiation, osteosarcoma biology, and neuroinflammation. This guide translates a recent rosemary-root natural-product study into practical dose-response, control, and troubleshooting strategies.
-
Dacomitinib Workflows for ErbB and Ferroptosis Research
2026-08-19
Dacomitinib (PF-00299804) enables durable ErbB pathway perturbation in resistant lung and breast cancer models, while offering an exploratory bridge to mitochondrial ferroptosis research. This guide translates its pan-HER mechanism into practical dosing, signaling, cell-death, and troubleshooting workflows without overstating evidence from colorectal cancer studies.